Get the Stockscreener App
2.01
6.07%
-0.13
Inmune Bio Inc stock is traded at $2.01, with a volume of 460.67K.
It is down -6.07% in the last 24 hours and up +32.24% over the past month.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$2.14
Open:
$2.15
24h Volume:
460.67K
Relative Volume:
1.00
Market Cap:
$53.44M
Revenue:
$155.00K
Net Income/Loss:
$-30.01M
P/E Ratio:
-1.2036
EPS:
-1.67
Net Cash Flow:
$-11.98M
1W Performance:
+5.24%
1M Performance:
+32.24%
6M Performance:
-74.62%
1Y Performance:
-58.73%
1-Day Range:
$2.005
$2.19
1-Week Range:
$1.89
$2.30
52-Week Range:
$1.38
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
2.01 | 56.89M | 155.00K | -30.01M | -11.98M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
Aug Closing: Is INmune Bio Inc stock resilient to inflationTrade Risk Report & Expert Verified Movement Alerts - moha.gov.vn
Praetorian PR LLC Sells 863,000 Shares of INmune Bio, Inc. $INMB - MarketBeat
Inmune Bio Ends Sales Agreement with RBC and BTIG - TipRanks
Can INmune Bio Stock Hold Up When Markets Turn? - Trefis
Can INmune Bio (NASDAQ:INMB) Afford To Invest In Growth? - Sahm
Would You Still Hold INmune Bio Stock If It Fell 30%? - Trefis
Inmune Bio Unveils Promising Alzheimer’s Trial Data - MSN
Insider Sell: Why INmune Bio Inc stock could see breakout soonJuly 2025 Momentum & AI Enhanced Market Trend Forecasts - moha.gov.vn
Retail Trends: Can INmune Bio Inc stock beat analyst upgradesMarket Activity Report & Verified Chart Pattern Signals - BỘ NỘI VỤ
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as Inmune Bio's CORDStrom?? Platform - marketscreener.com
INMB: INmune Bio Highlights Future Potential of MSC Therapies - GuruFocus
INmune Bio, Inc. Announces Publication on Future Applications of Mesenchymal Stromal Cell Therapies - Quiver Quantitative
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform - The Manila Times
INmune Bio Inc Stock Analysis and ForecastSell Signals and Alerts & Turn Data into Profits With Our Strategies - earlytimes.in
Inmune Bio Updates Executive Employment Agreements - TipRanks
INMB SEC FilingsInmune Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Could INmune Bio Unlock Value With Upcoming Regulatory Catalysts And Clinical Readouts? - RTTNews
Why INmune Bio Inc. stock could see breakout soonWeekly Loss Report & Daily Momentum Trading Reports - Newser
Can INmune Bio Inc. stock beat analyst upgradesStock Surge & Free Technical Confirmation Trade Alerts - Newser
Can INmune Bio Stock Recover If Markets Fall? - Trefis
Can INmune Bio Inc. stock sustain revenue growthJuly 2025 News Drivers & AI Powered Buy and Sell Recommendations - Newser
INmune Bio reports promising Alzheimer’s drug data at CTAD conference By Investing.com - Investing.com Canada
INmune Bio stock falls after new Alzheimer’s trial data By Investing.com - Investing.com Nigeria
INmune Bio stock falls after new Alzheimer’s trial data - Investing.com
INmune Bio (INMB) Reveals Promising Phase 2 Neuroimaging Data for Alzheimer's Treatment - GuruFocus
INmune Bio (INMB) Reveals Promising Phase 2 Neuroimaging Data fo - GuruFocus
INmune Bio reports promising Alzheimer’s drug data at CTAD conference - Investing.com
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients - The Manila Times
INmune Bio, Inc. Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595?s Evidence Base in High-Inflammation Alzheimer's Patients - marketscreener.com
What drives INmune Bio Inc stock priceREITs Market Trends & Consistent High Yield Stocks - earlytimes.in
Inmune Bio announces new executive employment agreements with compensation details - Investing.com Nigeria
Inmune Bio announces new executive employment agreements with compensation details By Investing.com - Investing.com South Africa
Inmune Bio Announces New Executive Employment Agreements - TipRanks
How INmune Bio Inc. stock performs in high volatility marketsTrade Volume Summary & Technical Pattern Alert System - moha.gov.vn
Block Trades: Why analysts upgrade INmune Bio Inc. stockTrade Analysis Report & High Win Rate Trade Alerts - BỘ NỘI VỤ
Is INmune Bio Inc. stock positioned for long term growth2025 Technical Overview & Technical Buy Zone Confirmation - newser.com
Analyzing recovery setups for INmune Bio Inc. investorsMarket Sentiment Report & Verified Swing Trading Watchlist - newser.com
Is INmune Bio Inc. a candidate for recovery playWeekly Gains Report & Consistent Profit Alerts - newser.com
Why INmune Bio Inc. stock is a value investor pickRisk Management & Daily Entry Point Alerts - newser.com
Heatmap analysis for INmune Bio Inc. and competitorsWeekly Earnings Recap & Real-Time Chart Breakout Alerts - newser.com
Short interest data insights for INmune Bio Inc.Market Trend Review & Verified Technical Signals - newser.com
How INmune Bio Inc. stock benefits from global expansionMarket Sentiment Summary & Reliable Price Action Trade Plans - newser.com
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):